Harel Insurance Investments & Financial Services Ltd. Purchases 587 Shares of Thermo Fisher Scientific Inc. $TMO

Harel Insurance Investments & Financial Services Ltd. boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 56.2% during the second quarter, Holdings Channel.com reports. The fund owned 1,632 shares of the medical research company’s stock after acquiring an additional 587 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.’s holdings in Thermo Fisher Scientific were worth $662,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Revolve Wealth Partners LLC raised its position in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares during the last quarter. Lafayette Investments Inc. raised its position in shares of Thermo Fisher Scientific by 2.4% during the second quarter. Lafayette Investments Inc. now owns 927 shares of the medical research company’s stock valued at $376,000 after buying an additional 22 shares during the last quarter. Rossmore Private Capital raised its position in shares of Thermo Fisher Scientific by 0.5% during the first quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company’s stock valued at $2,315,000 after buying an additional 24 shares during the last quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH raised its position in shares of Thermo Fisher Scientific by 3.1% during the second quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 803 shares of the medical research company’s stock valued at $326,000 after buying an additional 24 shares during the last quarter. Finally, Somerville Kurt F raised its position in shares of Thermo Fisher Scientific by 1.6% during the second quarter. Somerville Kurt F now owns 1,605 shares of the medical research company’s stock valued at $651,000 after buying an additional 25 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the topic of several recent analyst reports. UBS Group lifted their price objective on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a research report on Thursday, October 23rd. Raymond James Financial reissued an “outperform” rating and issued a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. HSBC reissued a “hold” rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Morgan Stanley raised their target price on shares of Thermo Fisher Scientific from $560.00 to $656.00 and gave the company an “overweight” rating in a report on Tuesday, October 28th. Finally, William Blair started coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They issued an “outperform” rating for the company. Nineteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $601.65.

Thermo Fisher Scientific Stock Up 2.2%

NYSE TMO opened at $568.25 on Monday. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The company has a fifty day moving average of $510.86 and a two-hundred day moving average of $457.89. The firm has a market capitalization of $214.58 billion, a price-to-earnings ratio of 32.83, a PEG ratio of 3.27 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. During the same period last year, the company earned $5.28 earnings per share. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $574.15, for a total value of $229,660.00. Following the completion of the sale, the executive vice president directly owned 21,152 shares in the company, valued at $12,144,420.80. The trade was a 1.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares of the company’s stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 54,420 shares of company stock worth $28,134,684 over the last three months. 0.33% of the stock is owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.